Bionic Vision Technologies is dedicated to developing effective and innovative implantable retinal prostheses (“bionic eyes”) for patients who have lost vision due to Retinitis Pigmentosa. Their approach is based on proven technology and data from early prototype investigations that form part of a core product pipeline.
Bioregulatory Consulting (BRC) provides a specialised regulatory and development service to the biotechnology and pharmaceutical industries. BRC is a privately held company, based in Melbourne, which was founded in February 2002.
Bioshares is Australia's leading biotech stock report. Bioshares delivers independent investment research to investors on Australian biotech, pharmaceutical and healthcare companies.
Blue Curve are medical device design and safety engineering experts, working exclusively with medical devices. From lab bench to market, having a specialist focus allows Blue Curve to go deep with your product.
At Boehringer Ingelheim, the purpose is simply to ‘Make More Health’ - for patients, people and community.
Brien Holden Vision Institute believes that sight is a fundamental right for everyone, everywhere. The Institute develops new solutions for vision care, especially refractive error, and work to eliminate vision impairment and avoidable blindness, thereby improving quality of life for people in need and helping to reduce disability and poverty.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Cancer Therapeutics CRC (CTx) is in the business of finding cures for cancer.
Cancer Trials Australia (CTA) is a member-based, clinical trial network organisation.
Carina Biotech is a spin-out company from the CRC for Cell Therapy Manufacturing (CTM@CRC Ltd). Carina serves as an IP development and commercialisation vehicle for T-cell immunotherapy related technologies, in particular, chimeric antigen receptor T cell (CAR-T) technologies.
Australia’s leading regenerative medicine researchers have come together in a coordinated, collaborative fashion to support the creation of CCRM Australia.
Celgene is a global biopharmaceutical company committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first.
Cell Therapies Pty Ltd (CTPL) is a leading cGMP manufacturer and distributor of cellular therapies. CTPL has operated TGA regulated cell processing facilities from Melbourne Australia, through strong clinical ties across multiple therapeutic areas. The company's facilities and capabilities are commercially available on a fee-for-service basis and have been used by the world’s leading cellular therapies companies.
Cenofex Innovations is an early stage medical device company using a proprietary technology to treat lymphedema. Caused by a poorly functioning lymphatic system, lymphedema is a debilitating, life-long condition characterised by the painful swelling of a limb or body region.
The company's vision is to create a vibrant economic future for Western Australia, based on sustainable high-knowledge, high-value and high-growth industries.
Clevertar is an award-winning Australian digital health company that brings behavior changing ‘relational agents’ to healthcare. The company was born out of research showing that autonomous virtual characters influence human behavior similar to a human interaction, and recent developments enable this to be achieved at a fraction of the cost.
CMAX Clinical Research is Australia’s longest established independent facility for clinical trials, delivering early phase clinical trial results to global pharmaceutical, biotechnology and device companies since 1993.
Cochlear is the global leader in implantable hearing solutions including cochlear, bone conduction and acoustic implants. We are a proudly Australian, globally successful company.
Cook Australia manufactures a diverse range of medical products for its home customers and for Cook distributors and subsidiaries around the world. Originally focused on angiographic and interventional devices, the company's concentration has expanded to include other items, particularly those needed for use with in vitro fertilisation and assisted reproduction procedures.
The Corneal Research Group is led by Prof Gerard Sutton and Dr Con Petsoglou to address cornea blindness within the community. The main research area include corneal bioengineering (corneal regeneration medicine), endothelial disease and keratoconus.